Cyclacel Pharmaceuticals (FRA:UXI) Debt-to-Equity : 0.06 (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Cyclacel Pharmaceuticals Debt-to-Equity?

Cyclacel Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. Cyclacel Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.03 Mil. Cyclacel Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €0.56 Mil. Cyclacel Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2023 was 0.06.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cyclacel Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

FRA:UXI' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.03 Max: 0.1
Current: 0.06

During the past 13 years, the highest Debt-to-Equity Ratio of Cyclacel Pharmaceuticals was 0.10. The lowest was 0.00. And the median was 0.03.

FRA:UXI's Debt-to-Equity is ranked better than
69.85% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs FRA:UXI: 0.06

Cyclacel Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Cyclacel Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cyclacel Pharmaceuticals Debt-to-Equity Chart

Cyclacel Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.10

0.03

0.01

0.06

Cyclacel Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.01	0.01	0.01	0.01	0.06

Competitive Comparison of Cyclacel Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Cyclacel Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyclacel Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cyclacel Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cyclacel Pharmaceuticals's Debt-to-Equity falls into.

Cyclacel Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cyclacel Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0.034)	/	0.557
	=	0.06

Cyclacel Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0.034)	/	0.557
	=	0.06

Cyclacel Pharmaceuticals (FRA:UXI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cyclacel Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cyclacel Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyclacel Pharmaceuticals (FRA:UXI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (FRA:UXI) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

CYCCP.PFD:USA CYCC:USA UXI:Germany

Address

200 Connell Drive, Suite 1500, Berkeley Heights, NJ, USA, 07922

Website

https://www.cyclacel.com

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.

Cyclacel Pharmaceuticals (FRA:UXI) Headlines

No Headlines